Current Report Filing (8-k)
20 August 2022 - 6:31AM
Edgar (US Regulatory)
0001261249
false
0001261249
2022-08-15
2022-08-15
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(D)
of the Securities Exchange Act of 1934
August 15, 2022
Date of report (Date of earliest event reported)
Agile Therapeutics,
Inc.
(Exact name of registrant as specified in its charter)
Delaware |
001-36464 |
23-2936302 |
(State or other jurisdiction
of incorporation) |
(Commission
File Number) |
(IRS Employer
Identification No.) |
|
500 College Road East, Suite 310
Princeton, New Jersey
(Address of principal executive offices) |
08540
(Zip Code) |
|
|
|
|
Registrant's telephone number, including area code (609) 683-1880
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K
filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨ Written communications
pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨ Soliciting material
pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨ Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨ Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of Each Class |
Trading Symbol(s) |
Name of each exchange on which registered |
Common stock, par value $0.0001 per share |
AGRX |
The Nasdaq Capital Market |
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange
Act of 1934 (§240.12b-2 of this chapter)
Emerging growth company ¨
If an emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant
to Section 13(a) of the Exchange Act. ¨
| Item 3.01 | Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. |
On August 15, 2022, Agile Therapeutics, Inc. (the “Company”)
received a deficiency letter from the Listing Qualifications Department (the “Staff”) of the Nasdaq Stock Market (“Nasdaq”)
notifying the Company that, for the preceding 30 consecutive business days, the closing bid price for the Company’s common stock
was below the minimum $1.00 per share requirement for continued inclusion on The Nasdaq Capital Market pursuant to Nasdaq Listing Rule
5550(a)(2) (the “Bid Price Requirement”).
The notification received has no immediate effect on the Company’s
Nasdaq listing. In accordance with Nasdaq rules, the Company has been provided an initial period of 180 calendar days, or until February
13, 2023 (the “Compliance Date”), to regain compliance with the Bid Price Requirement. If, at any time before the Compliance
Date, the closing bid price for the Company’s common stock is at least $1.00 for a minimum of 10 consecutive business days, the
Staff will provide the Company written confirmation of compliance with the Bid Price Requirement.
If the Company does not regain compliance with the Bid Price Requirement
by the Compliance Date, the Company may be eligible for an additional 180 calendar day compliance period. To qualify, the Company will
be required to meet the continued listing requirement for market value of publicly held shares and all other initial listing standards
for The Nasdaq Capital Market, with the exception of the Bid Price Requirement, and will need to provide written notice of its intention
to cure the deficiency during the second 180 calendar day compliance period.
If the Company does not regain compliance with the Bid Price Requirement
by the Compliance Date and is not eligible for an additional compliance period at that time, the Staff will provide written notification
to the Company that its common stock will be subject to delisting. At that time, the Company may appeal the Staff’s delisting determination
to a Nasdaq Hearings Panel. There can be no assurance that the Company will regain compliance or otherwise maintain compliance with any
of the other listing requirements.
The Company intends to monitor the closing bid price of its common
stock and may, if appropriate, consider available options to regain compliance with the Bid Price Requirement.
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, as amended, the Company has duly caused this report to be signed on its behalf by the undersigned hereunto duly
authorized.
|
Agile Therapeutics, Inc. |
|
|
|
Dated: August 19, 2022 |
By: |
/s/ Alfred Altomari |
|
Name: |
Alfred Altomari |
|
Title: |
President and Chief Executive Officer |
Agile Therapeutics (NASDAQ:AGRX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Agile Therapeutics (NASDAQ:AGRX)
Historical Stock Chart
From Apr 2023 to Apr 2024